Your browser doesn't support javascript.
loading
Addition of PI3K/AKT/mTOR inhibitors to fulvestrant for advanced HR+/HER2- breast cancer: a systematic review and meta-analysis.
Zhang, Tianqi; Xie, Danni; Ye, Xinhui; Wang, Yinuo; Sun, Xue; Zhao, Qingchun; Ren, Tianshu.
Afiliación
  • Zhang T; Bei Fang Hospital of Shenyang Pharmaceutical University, General Hospital of Northern Theater Command. No. 83, Wenhua Road, Shenhe District, Shenyang, 110016, China.
  • Xie D; Bei Fang Hospital of Shenyang Pharmaceutical University, General Hospital of Northern Theater Command. No. 83, Wenhua Road, Shenhe District, Shenyang, 110016, China.
  • Ye X; Department of Clinical Pharmacy, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenhe District, Shenyang, 110016, China.
  • Wang Y; Department of Clinical Pharmacy, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenhe District, Shenyang, 110016, China.
  • Sun X; Bei Fang Hospital of Shenyang Pharmaceutical University, General Hospital of Northern Theater Command. No. 83, Wenhua Road, Shenhe District, Shenyang, 110016, China.
  • Zhao Q; Bei Fang Hospital of Shenyang Pharmaceutical University, General Hospital of Northern Theater Command. No. 83, Wenhua Road, Shenhe District, Shenyang, 110016, China.
  • Ren T; Bei Fang Hospital of Shenyang Pharmaceutical University, General Hospital of Northern Theater Command. No. 83, Wenhua Road, Shenhe District, Shenyang, 110016, China.
Future Oncol ; 19(20): 1439-1450, 2023 Jun.
Article en En | MEDLINE | ID: mdl-37497628

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Systematic_reviews Límite: Female / Humans Idioma: En Revista: Future Oncol Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Systematic_reviews Límite: Female / Humans Idioma: En Revista: Future Oncol Año: 2023 Tipo del documento: Article País de afiliación: China